Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. This development marks a significant step forward in the field of systemic oncolytic targeted immunotherapies, offering hope for more effective cancer treatments.

The data presented highlights a novel genetic modification involving a chimeric CD55 receptor incorporated into the virus's envelope. This modification enhances the virus's resistance to rapid clearance by the humoral immune system following intravenous administration, a breakthrough that could improve the efficacy of systemic delivery to metastatic tumor sites. The implications of this advancement are profound, potentially leading to more effective treatments for non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs.

Calidi Biotherapeutics' pioneering efforts in developing an enveloped form of its proprietary oncolytic virus have previously demonstrated significant resistance to immune clearance compared to non-enveloped forms. The latest data on CLD-401 further solidify the company's position at the forefront of immuno-oncology research, with the potential to revolutionize cancer therapy by enabling systemic delivery and targeting of metastatic sites.

The significance of this announcement lies not only in the scientific advancement it represents but also in its potential impact on patients worldwide. By improving the delivery and efficacy of oncolytic viruses, Calidi Biotherapeutics is paving the way for innovative treatments that could offer new hope to those battling cancer. The data presented at ASCO 2025 underscores the importance of continued investment and research in biotechnology to address some of the most challenging medical conditions of our time.